Last updated: October 5, 2026
Next Choice is a levonorgestrel emergency-contraception product supplied as 0.75 mg tablets, historically taken as two tablets for a total 1.5 mg dose. Its formulation is a conventional immediate-release tablet using low-cost, widely available excipients. The strongest commercial opportunities are private-label supply, generic manufacturing, single-tablet conversion, improved packaging, and expanded retail or online distribution.
What is Next Choice?
Next Choice contains levonorgestrel, a synthetic progestin used for emergency contraception. The historical product presentation used two 0.75 mg tablets taken 12 hours apart. Current emergency-contraception products commonly use a single 1.5 mg dose.
| Attribute |
Next Choice profile |
| Active ingredient |
Levonorgestrel |
| Strength |
0.75 mg per tablet |
| Total dose |
1.5 mg |
| Dosage form |
Immediate-release oral tablet |
| Route |
Oral |
| Product type |
Emergency contraceptive |
| Main competitive products |
Plan B One-Step, Take Action, My Choice, Aftera, store-brand levonorgestrel |
| Biosimilar relevance |
None |
| Primary formulation issue |
Low-dose content uniformity |
| Delivery technology |
Conventional compressed tablet |
The low amount of levonorgestrel relative to total tablet mass makes blend uniformity, segregation control, and assay precision more important than high drug loading. The product does not require controlled release, sterile manufacturing, biologic stabilization, or specialized absorption technology.
What excipients are used in Next Choice tablets?
Public labeling for levonorgestrel tablet products identifies an excipient system that includes lactose monohydrate, starch, colloidal silicon dioxide, and magnesium stearate. Exact composition should be verified against the applicable approved product labeling before development or regulatory submission (National Library of Medicine, n.d.; U.S. Food and Drug Administration, n.d.-a).
| Excipient |
Function |
Commercial rationale |
| Lactose monohydrate |
Diluent and tablet-mass builder |
Low cost, broad supply, established oral use |
| Starch |
Binder, disintegrant, or filler |
Supports tablet formation and rapid breakup |
| Colloidal silicon dioxide |
Glidant and flow aid |
Improves powder flow at low drug concentration |
| Magnesium stearate |
Lubricant |
Reduces tooling friction and tablet-ejection force |
This excipient platform is technically conventional and readily reproducible. Its value is manufacturing robustness rather than formulation exclusivity.
What formulation risks arise from the Next Choice excipient system?
The principal risks are linked to the low active-ingredient dose.
Poor particle-size compatibility between levonorgestrel and the diluent can cause segregation. Inadequate premixing can produce assay and content-uniformity failures. Excessive lubrication with magnesium stearate can reduce wettability and slow dissolution. Excessive colloidal silicon dioxide can alter powder flow and bulk density.
Key development variables include:
- Particle-size distribution of levonorgestrel and lactose.
- Premix design and order of addition.
- Blend time and scale-up parameters.
- Lubricant concentration and lubrication time.
- Tablet hardness and porosity.
- Disintegration and dissolution performance.
- Moisture exposure during storage.
- Packaging protection from humidity and light.
A direct-compression process may reduce manufacturing cost and processing time. Roller compaction or wet granulation may offer better segregation and flow control where the active ingredient is difficult to handle. The appropriate process depends on excipient grade, tablet weight, equipment, and target specifications.
How can manufacturers optimize the Next Choice excipient strategy?
How can content uniformity be improved?
A controlled premix or ordered blending process is central to product quality. Manufacturers can evaluate narrow particle-size excipient grades, pre-blended carriers, or co-processed filler systems to reduce segregation.
Lactose remains commercially attractive, but particle-size distribution, moisture content, and bulk density should be tightly controlled. The objective is consistent distribution of the low-dose active ingredient throughout the batch.
How can tablet disintegration be improved?
Emergency contraception is an acute-use product. A rapid-disintegration profile can support consumer expectations and reduce dissolution risk without requiring a specialized delivery system.
Potential alternatives include:
- Crospovidone.
- Croscarmellose sodium.
- Pregelatinized starch.
- Direct-compression lactose.
- Co-processed filler-disintegrant systems.
Any excipient substitution requires evaluation of assay, content uniformity, dissolution, stability, tablet strength, and bioequivalence.
Can Next Choice be converted to a single 1.5 mg tablet?
Yes, subject to the applicable regulatory pathway. A single-tablet presentation could reduce administration errors, simplify packaging, and improve consumer convenience. It may require a larger tablet or a higher-concentration blend, with corresponding evaluation of flow, compression, disintegration, and dissolution.
The single-tablet format is the most commercially relevant formulation upgrade because it improves the user experience without requiring a new delivery technology.
Is a lactose-free product commercially attractive?
A lactose-free formulation could support differentiated positioning for selected consumer groups and international markets. Possible replacements include microcrystalline cellulose, mannitol, starch-based fillers, and co-processed excipients.
The commercial benefit may be limited in the United States because lactose content in an oral tablet is generally low and is not a major purchasing barrier for most consumers. Ingredient substitution could increase cost without creating a meaningful clinical benefit.
Can packaging create commercial differentiation?
Yes. Packaging may provide a lower-risk path to product differentiation than core formulation changes.
Potential options include:
- Unit-dose blister packaging.
- High-barrier foil packaging.
- Discreet wallet packs.
- Tamper-evident formats.
- Multilingual instructions.
- QR-linked dosing information.
- Distribution packaging designed for hot and humid climates.
For an emergency product, availability and ease of use can have greater commercial value than modest excipient changes.
What FDA regulatory status applies to Next Choice?
Levonorgestrel emergency contraception has moved from prescription distribution toward broad nonprescription access. In 2013, FDA approved Plan B One-Step for nonprescription use without age or point-of-sale restrictions (U.S. Food and Drug Administration, 2013).
That decision increased competition across the levonorgestrel emergency-contraception market. Brand recognition, pharmacy distribution, retailer access, and price now play a larger role than prescription status.
What is the Orange Book status of Next Choice?
The commercial value of a conventional Next Choice tablet is unlikely to depend on a durable Orange Book patent estate. Levonorgestrel is an established small molecule, and the product uses conventional immediate-release technology.
Any eligible patent protection would need to cover a qualifying drug product, formulation, method of use, delivery system, or manufacturing process. A claim directed only to the use of common excipients would be unlikely to create a strong market barrier.
Current Orange Book status, applicant information, marketing status, and patent listings should be verified through the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations database because listings can change (U.S. Food and Drug Administration, n.d.-b).
When did Next Choice lose exclusivity?
Next Choice does not have meaningful remaining new-chemical-entity or orphan exclusivity. Levonorgestrel emergency contraception has been marketed for decades, and competing products are available through generic and equivalent-product pathways.
| Exclusivity category |
Assessment |
| New chemical entity exclusivity |
Not applicable |
| Orphan exclusivity |
Not applicable |
| Biosimilar exclusivity |
Not applicable |
| Active-ingredient exclusivity |
Commercially exhausted |
| Conventional tablet exclusivity |
Limited |
| Formulation exclusivity |
Possible only if supported by eligible unexpired claims |
| Generic entry risk |
High |
| Patent-based barrier |
Low for conventional tablets |
Commercial protection is therefore based mainly on price, supply reliability, retail relationships, brand recognition, packaging, and consumer access.
What patents could protect a Next Choice successor?
A conventional formulation using lactose, starch, colloidal silicon dioxide, and magnesium stearate is unlikely to support a strong standalone patent estate. Potentially protectable categories include:
- Single-tablet 1.5 mg formulations.
- Orally disintegrating tablets.
- Chewable formulations.
- Taste-masking systems.
- Defined excipient ratios linked to performance.
- Packaging and dispensing systems.
- Manufacturing processes controlling low-dose blend uniformity.
- Methods designed to reduce administration errors.
A formulation patent would need technically specific claims with measurable advantages and sufficient differentiation from prior art. Broad claims to a levonorgestrel tablet using conventional excipients would face substantial validity and design-around pressure.
Which companies compete with Next Choice?
The market includes branded products, store brands, online products, and international levonorgestrel products.
| Competitor category |
Main positioning |
| Plan B One-Step |
Premium recognized brand |
| Store-brand levonorgestrel |
Low-price pharmacy and mass-retail alternative |
| Online emergency-contraception brands |
Convenience and discreet delivery |
| International products |
Access and local-market affordability |
| Copper intrauterine device |
Non-oral emergency contraception and ongoing contraception |
A Next Choice-derived product would compete most effectively as a low-cost, single-dose product with broad pharmacy, mass-retail, and online distribution.
What commercial opportunities exist for Next Choice excipients?
Private-label and retailer products
Retailers can use a conventional levonorgestrel excipient platform to launch lower-cost store brands. The simple formulation supports multiple contract manufacturers and reduces dependence on specialized production assets.
Excipient supplier partnerships
Excipient suppliers can target this category with:
- Direct-compression lactose.
- Low-moisture filler systems.
- Co-processed filler-disintegrants.
- High-purity colloidal silicon dioxide.
- Low-peroxide excipient grades.
- Lubricant systems optimized for rapid dissolution.
The strongest sales proposition is process consistency, not novel pharmacology.
Single-dose conversion
A 1.5 mg single-tablet product offers the clearest product-development opportunity. It supports easier administration, simpler labeling, smaller packaging, and more direct comparison with current OTC competitors.
Chewable and orally disintegrating products
A chewable or orally disintegrating product could target consumers who have difficulty swallowing tablets. The main technical issue is taste. Development may require sweeteners, flavors, polymeric taste blockers, and specialized compression processes.
This strategy could create product differentiation, but it would increase cost and manufacturing complexity. It is more attractive for premium or direct-to-consumer positioning than for the lowest-cost generic segment.
Geographic adaptation
Excipient selection should account for:
- Climatic-zone stability.
- Local excipient availability.
- Pharmacopoeial requirements.
- Dietary and religious restrictions.
- Packaging infrastructure.
- Distribution conditions.
- Regulatory requirements in each market.
A lactose-free or vegetarian-positioned product may have more value in selected international markets than in the United States.
What generic launch risks affect a Next Choice product?
The main launch risks are regulatory, manufacturing, and commercial rather than patent-based.
| Risk |
Potential impact |
Mitigation |
| Content-uniformity failure |
Application delay or batch rejection |
Validated premix and blending controls |
| Dissolution variability |
Bioequivalence or quality failure |
Optimize excipient grade and lubrication |
| Moisture instability |
Reduced shelf life |
High-barrier blister packaging |
| Price compression |
Lower gross margins |
High-volume manufacturing |
| Retail substitution |
Weak brand retention |
Private-label and channel contracts |
| OTC competition |
Limited prescription demand |
Broad retail and online distribution |
| Supply interruption |
Product stockouts |
Dual sourcing of critical excipients |
| Labeling mismatch |
Regulatory action |
Maintain current market-specific labeling |
Paragraph IV litigation risk is likely to be limited for a mature, conventional levonorgestrel tablet unless a later product relies on an unexpired formulation, packaging, or method patent. The absence of a strong patent barrier does not guarantee rapid commercial success. Regulatory approval, manufacturing capacity, product availability, and pricing will determine market entry.
How strong is the Next Choice patent estate?
The patent estate is weak as a standalone commercial moat for a conventional two-tablet levonorgestrel product. A stronger estate would require a differentiated product with enforceable claims covering:
- A single-tablet formulation with defined performance characteristics.
- A robust orally disintegrating tablet.
- A validated taste-masking system.
- A proprietary dispensing or packaging system.
- A manufacturing process that creates measurable quality benefits.
Patent value would depend on claim scope, expiration dates, prosecution history, prior art, and the ability of competitors to design around the claims.
Key Takeaways
- Next Choice is a conventional immediate-release levonorgestrel tablet.
- The historical excipient system includes lactose monohydrate, starch, colloidal silicon dioxide, and magnesium stearate.
- Low-dose content uniformity is the primary technical challenge.
- A single 1.5 mg tablet is commercially more attractive than a two-tablet presentation.
- The strongest opportunities are private-label manufacturing, generic supply, improved packaging, online distribution, and single-dose conversion.
- Common excipients are unlikely to provide meaningful standalone patent protection.
- FDA nonprescription access has increased competition from brands, store brands, and online products.
- Manufacturing reliability, supply continuity, price, and retail access are more important than excipient novelty.
FAQs about Next Choice formulation and commercial strategy
Can Next Choice be reformulated without lactose?
Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, starch-based fillers, or co-processed excipients. The replacement must maintain content uniformity, compression performance, disintegration, dissolution, stability, and regulatory comparability.
Is a single-tablet levonorgestrel product commercially superior to Next Choice?
Generally, yes. A single 1.5 mg tablet reduces administration complexity and supports simpler packaging. Its advantage is strongest in retail, OTC, and online channels.
Do excipients create patent protection for levonorgestrel emergency contraception?
Usually not by themselves. Protection would require a technically specific, patent-eligible formulation or process with claims that competitors cannot easily design around.
Is biosimilar competition relevant to Next Choice?
No. Levonorgestrel is a chemically synthesized small molecule. Competition arises through generic or equivalent-drug pathways rather than biosimilar regulation.
What is the most valuable formulation improvement for a Next Choice successor?
The strongest near-term opportunity is a stable single-tablet 1.5 mg product with rapid disintegration, reliable content uniformity, discreet high-barrier packaging, and low manufacturing cost.
References
-
National Library of Medicine. (n.d.). DailyMed: Levonorgestrel tablet product labeling. https://dailymed.nlm.nih.gov/
-
U.S. Food and Drug Administration. (2013). FDA approves Plan B One-Step emergency contraceptive for non-prescription use without age or point-of-sale restrictions. https://www.fda.gov/
-
U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drug products and labeling. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book/
